US20180327801A1 - METHOD FOR PREPARING RECOMBINANT PROTEINS THROUGH REDUCTION OF rnpA GENE EXPRESSION - Google Patents
METHOD FOR PREPARING RECOMBINANT PROTEINS THROUGH REDUCTION OF rnpA GENE EXPRESSION Download PDFInfo
- Publication number
- US20180327801A1 US20180327801A1 US16/027,478 US201816027478A US2018327801A1 US 20180327801 A1 US20180327801 A1 US 20180327801A1 US 201816027478 A US201816027478 A US 201816027478A US 2018327801 A1 US2018327801 A1 US 2018327801A1
- Authority
- US
- United States
- Prior art keywords
- protein
- expression
- gene
- srna
- rnpa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 114
- 101150051303 rnpA gene Proteins 0.000 title claims abstract description 27
- 238000000034 method Methods 0.000 title claims abstract description 20
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title abstract description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title abstract description 9
- 230000009467 reduction Effects 0.000 title description 6
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 211
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 162
- 108020004566 Transfer RNA Proteins 0.000 claims abstract description 54
- 102000004167 Ribonuclease P Human genes 0.000 claims abstract description 25
- 108090000621 Ribonuclease P Proteins 0.000 claims abstract description 25
- 244000005700 microbiome Species 0.000 claims abstract description 22
- 238000004519 manufacturing process Methods 0.000 claims abstract description 15
- 238000012258 culturing Methods 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 108090000250 sortase A Proteins 0.000 claims description 6
- 102000018832 Cytochromes Human genes 0.000 claims description 3
- 108010052832 Cytochromes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- -1 antibody Proteins 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 230000001965 increasing effect Effects 0.000 abstract description 23
- 239000013612 plasmid Substances 0.000 description 46
- 239000013598 vector Substances 0.000 description 25
- 230000001939 inductive effect Effects 0.000 description 24
- 108091008146 restriction endonucleases Proteins 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 15
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 13
- 239000002609 medium Substances 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 9
- 238000001962 electrophoresis Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000008188 pellet Substances 0.000 description 8
- 230000014616 translation Effects 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 101100382207 Arabidopsis thaliana CYP98A3 gene Proteins 0.000 description 6
- 101100182965 Escherichia coli (strain K12) maeA gene Proteins 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 5
- 238000010804 cDNA synthesis Methods 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 229960005091 chloramphenicol Drugs 0.000 description 5
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 101100132917 Arabidopsis thaliana ATR1 gene Proteins 0.000 description 4
- 101100152598 Arabidopsis thaliana CYP73A5 gene Proteins 0.000 description 4
- 101100478373 Bacillus subtilis (strain 168) srtD gene Proteins 0.000 description 4
- 101150116295 CAT2 gene Proteins 0.000 description 4
- 101100326920 Caenorhabditis elegans ctl-1 gene Proteins 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 101100126846 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) katG gene Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 101100208039 Rattus norvegicus Trpv5 gene Proteins 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 239000013600 plasmid vector Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 101150087718 srtA gene Proteins 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 239000012137 tryptone Substances 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 101710104378 Putative malate oxidoreductase [NAD] Proteins 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 229940114081 cinnamate Drugs 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical group 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108010024655 4-hydroxybutyrate CoA-transferase Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000588722 Escherichia Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000012741 Laemmli sample buffer Substances 0.000 description 2
- 241000238902 Nephila clavipes Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- 239000007984 Tris EDTA buffer Substances 0.000 description 2
- 101150063416 add gene Proteins 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920001872 Spider silk Polymers 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007852 inverse PCR Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 101150009573 phoA gene Proteins 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/26—Endoribonucleases producing 5'-phosphomonoesters (3.1.26)
- C12Y301/26005—Ribonuclease P (3.1.26.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
Definitions
- the present invention relates to a method for improving the production of a recombinant protein in a recombinant microorganism, and more particularly to a method for improving the production of a recombinant protein by use of a recombinant microorganism into which a gene encoding a target protein and an sRNA against a gene encoding ribonuclease P are introduced.
- the useful protein to be produced is larger in size than a naturally occurring protein or is difficult to express, many problems may arise. If the size of a protein is large, translation of the protein may be difficult due to lack of messanger RNA (mRNA), and thus expression of the desired full-length protein may be difficult.
- mRNA messanger RNA
- a recombinant protein that is not naturally present in E is not naturally present in E.
- coli may be difficult to express, due to proteolysis and RNase-induced degradation of mRNA (GoBringer et al., J Bacteriol., 188: 6816, 2006; Olson et al., PLoS Pathog., 7(2): e1001287, 2011; Jung et al., Biochem Biophys Res Commun., 186(3):1463, 1992; Altman et al., Phil Trans R Soc., 366, 2011; Turrini et al., PLos One., 7(3): e32456, 2012).
- the present inventors have made extensive efforts to develop a protein expression system for increasing the production of a difficult-to-express foreign protein, and as a result, have found that, when expression of the rnpA gene (which is a component of ribonuclease P) in a process of expressing the foreign protein by introducing a gene encoding the foreign protein is reduced, expression of the difficult-to-express foreign protein increases, thereby completing the present invention.
- the rnpA gene which is a component of ribonuclease P
- Another object of the present invention is to provide a method for producing a target protein by culturing the above-described recombinant microorganism.
- the present invention provides a recombinant vector for expressing a target protein, which comprises a gene encoding the target protein and an sRNA against a gene encoding ribonuclease P, and a recombinant microorganism into which the recombinant vector is introduced.
- the present invention also provides a recombinant microorganism into which a gene encoding a target protein and an sRNA against a gene encoding ribonuclease P are introduced.
- the present invention also provides a method for producing a target protein, the method comprising the steps of: (a) producing the target protein by culturing the above-described recombinant microorganism and inducing expression of the target protein in the recombinant microorganism; and (b) recovering the produced target protein.
- the present invention also provides a method for producing a target protein, comprising the steps of: expressing and producing the target protein by culturing a recombinant microorganism into which a gene encoding the target protein is introduced; and recovering the produced target protein, wherein expression of ribonuclease P is reduced to increase expression of the target protein.
- FIG. 1 is a gene map of the plasmid pTetly2glyAN-rnpA(sRNA).
- FIG. 2 shows the results of analyzing expression levels of a silk protein consisting of 16 repeats and a silk protein consisting of 32 repeats by SDS-PAGE.
- Lane 1 a marker showing protein standard molecular weight
- lanes 2 and 3 the results of inducing protein expression in a stain transformed with the plasmid pSH16 at an OD600 of 0.4
- lanes 4 and 5 the results of inducing protein expression in a strain transformed with the plasmid pSH16 and pACYC184-rnpA(sRNA) at an OD600 of 0.4
- lanes 6 and 7 the results of inducing protein expression in a strain transformed with the plasmid pSH32 at an OD 600 of 0.4
- lanes 8 and 9 the results of inducing protein expression in a strain transformed with the plasmid pSH32 and pACYC184-rnpA(sRNA) at an OD600 of 0.4.
- FIG. 3 shows the results of analyzing expression levels of a silk protein consisting of 64 repeats by SDS-PAGE.
- lane 1 a marker showing protein standard molecular weight
- lane 2 the result of inducing protein expression in a strain transformed with pSH64 at an OD600 of 0.4
- lane 3 the result of inducing protein expression in a strain transformed with the plasmid pSH64 and pACYC184-rnpA(sRNA) at an OD600 of 0.4.
- FIG. 4A shows the results of analyzing expression levels of a silk protein consisting of 96 repeats by SDS-PAGE.
- lane 1 a marker showing protein standard molecular weight
- lane 2 the result of inducing protein expression in a strain transformed with pSH96 at an OD 600 of 0.4
- lane 3 the result of inducing protein expression in a strain transformed with the plasmid pSH96 and pACYC184-rnpA(sRNA) at an OD 600 of 0.4.
- FIG. 4B shows the results obtained by inducing protein expression in strains transformed with the plasmid pSH96 and the plasmid pSH96 plus pTetgly2glyAN-rnpA(sRNA), respectively, at an OD 600 of 0.4, analyzing protein expression levels by SDS-PAGE, quantifying the protein expression levels using a densitometer, and then averaging the protein expression levels.
- FIG. 5 shows the result of analyzing expression levels of a silk protein consisting of 128 repeats by SDS-PAGE.
- lane 1 a marker showing protein standard molecular weight
- lane 2 the result of inducing protein expression in a strain transformed with pSH128 at an OD600 of 0.4
- lane 3 the result of inducing protein expression in a strain transformed with pSH128 and pACYC184-rnpA(sRNA) at an OD 600 of 0.4.
- FIG. 6 is a graph showing the results of examining whether the level of intracellular mRNA is increased by reducing expression of the rnpA gene.
- FIG. 7A is a graph showing the amount of a silk protein consisting of 96 repeats, produced by fed-batch culture, and FIG. 7B shows the results of electrophoresis of the protein.
- FIG. 8 shows the results of electrophoresis performed using a system for reducing expression of the rnpA gene according to the present invention in order to confirm increased expressions of difficult-to-express proteins other than the silk protein.
- electrophoresis image (a) shows the results of analyzing the expression level of malic enzyme (SfcA) by SDS-PAGE.
- Electrophoresis image shows the results of analyzing the expression level of Cat2 by SDS-PAGE.
- Electrophoresis image (c) shows the results of analyzing the expression level of SrtA by SDS-PAGE.
- Electrophoresis image shows the results of analyzing the expression level of CYP73A5 by SDS-PAGE.
- Electrophoresis image shows the results of analyzing the expression level of CYP98A3 by SDS-PAGE.
- lanes 1 and 3 the results of inducing protein expression in a strain transformed with CYP98A3 at an OD 600 of 0.4
- lanes 4 and 5 the results of inducing protein expression in a strain transformed with CYP98A3-rnpA(sRNA) at an OD 600 of 0.4
- the present inventors have developed a method for improving expression of a difficult-to-express recombinant protein, which was not easily produced in the prior art, in a recombinant microorganism by reducing expression of ribonuclease P to increase the mRNA level of a useful protein in cells.
- the term “difficult-to-express protein” refers to a protein having a molecular weight of 50 kDa or more.
- the present invention is directed to a recombinant vector for expressing a target protein, which comprises a gene encoding the target protein and an sRNA against a gene encoding ribonuclease P, and to a recombinant microorganism transformed with the recombinant vector.
- the target protein may be a protein selected from among difficult-to-express proteins silk proteins, antibodies, enzymes, cytochromes, and sortase A, but is not limited thereto.
- the sRNA may be an sRNA against an rnpA gene, and may have a nucleotide sequence set forth in any one of SEQ ID NOs: 1 to 3, but is not limited thereto as long as it reduces the expression of an rnpA gene.
- examples of microorganisms for production of proteins may include Escherichia, Pseudomonas, Saccharomyces, and the like, and may be preferably an Escherichia microorganism, most preferably E. coli.
- E. coli can be easily industrialized since genetic information and culture conditions that are widely used industrially are very well known.
- a recombinant E. coli strain was constructed by transformation with a gene encoding a silk protein resulting from modification of a dragline silk protein obtained from Nephila clavipes, a nucleotide sequence encoding glycine tRNA, and an sRNA for reducing expression of the RnpA that is a component of ribonuclease P.
- the constructed recombinant E. coli strain was cultured. As a result, it could be seen that the protein of the silk protein increased 3-fold or more.
- a malic enzyme-encoding gene sfcA
- a sortase A-encoding gene srtA
- a 4-hydroxybutyrate coenzyme A transferase-encoding gene Cat2
- the cytochrome P450 gene CYP73A5; cinnamate 4-hydrosylase and CYP98A3
- the present invention is directed to a recombinant microorganism into which a gene encoding a target protein and an sRNA against a gene encoding ribonuclease P are introduced.
- the gene encoding the target protein and the sRNA against the gene encoding ribonuclease P may be present in the respective vectors or may be incorporated into the microbial chromosome.
- the present invention is directed to a method for producing a difficult-to-express target protein, the method comprising the steps of: (a) producing the target protein by culturing the recombinant microorganism and inducing expression of the target protein in the recombinant microorganism; and (b) recovering the produced target protein.
- a recombinant E. coli strain was constructed by transformation with a gene encoding a silk protein, a nucleotide sequence encoding glycine tRNA, and an sRNA for reducing expression of the rnpA gene that is a component of ribonuclease P.
- the constructed recombinant E. coli strain was cultured. As a result, it could be seen that the protein of the silk protein increased 3-fold or more.
- the target protein may be a large protein having a molecular weight of 50 kDa or more as a difficult-to-express protein.
- the target protein may be a protein selected from a group consisting of silk proteins, antibodies, enzymes, cytochromes, and sortase A, but is not limited thereto.
- the present invention is directed to a method for producing a target protein, comprising the steps of: expressing and producing the target protein by culturing a recombinant microorganism into which a gene encoding the target protein is introduced; and recovering the produced target protein, wherein expression of ribonuclease P in the recombinant microorganism is reduced to increase expression of the target protein.
- the target protein may be a difficult-to-express protein or a protein having a molecular weight of 50 kDa or more, and a substance of inhibiting the expression of ribonuclease P may be added.
- sRNA small RNA
- sRNA refers to a short-length RNA, which is usually 200 or less nucleotides in length, which is not translated into protein and effectively inhibits the translation of a specific mRNA by complementary binding.
- ribosome binding site refers to a site where ribosome binds to mRNA for the transcription of the mRNA.
- the term “gene” is intended to have the broadest meaning, and the gene can encode a structural protein or a regulatory protein.
- the regulatory protein includes a transcriptional factor, a heat shock protein, or a protein that is involved in DNA/RNA replication, transcription and/or translation.
- the target gene whose expression is to be inhibited may be present as an extrachromosomal element.
- the term “vector” means a DNA construct containing a DNA sequence operably linked to a suitable control sequence capable of effecting the expression of the DNA in a suitable host.
- the vector may be a plasmid, a phage particle, or simply a potential genomic insert. Once incorporated into a suitable host, the vector may replicate and function independently of the host genome, or may in some instances, integrate into the genome itself.
- plasmid and vector are sometimes used interchangeably, as the plasmid is the most commonly used form of vector.
- the plasmid vector is preferably used.
- a typical plasmid vector which can be used for this purpose contains: (a) a replication origin by which replication occurs efficiently such that several hundred plasmid vectors per host cell are created; (b) an antibiotic-resistant gene by which host cells transformed with the plasmid vector can be selected; and (c) restriction enzyme cutting sites into which foreign DNA fragments can be inserted. Even if suitable restriction enzyme cutting sites are not present in the vector, the use of a conventional synthetic oligonucleotide adaptor or linker enables the easy ligation between the vector and the foreign DNA fragments. After ligation, the vector should be transformed into suitable host cells.
- the transformation can be easily achieved by the calcium chloride method or electroporation (Neumann, et al., EMBO J., 1:841, 1982).
- a publicly known expression vector in the art may be used as a vector for expressing sRNA according to the present invention.
- a nucleic acid sequence is operably linked when it is placed into arranged in a functional relationship with another nucleic acid sequence.
- the nucleotide sequence may be a gene and a control sequence(s) linked to be capable of expressing the gene when a suitable molecule binds to a control sequence(s) (e.g., transcription-activating protein).
- DNA for a pre-sequence or a secretory leader is operably linked to a DNA encoding a polypeptide when expressed as a pre-protein participating in secretion of the polypeptide; a promoter or an enhancer is operably linked to a coding sequence when affecting the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence when affecting the transcription of the sequence, or to a coding sequence when arranged to facilitate translation.
- the term “operably linked” means that the DNA linked sequences are contiguous, and in the case of the secretory leader, are contiguous and present in a reading frame.
- an enhancer is not necessarily contiguous. The linkage between these sequences is performed by ligation at a convenient restriction enzyme site. However, when this site does not exist, a synthetic oligonucleotide adaptor or a linker is used according to a conventional method.
- the present invention is directed to a recombinant microorganism into which an expression vector comprising a nucleic acid encoding the sRNA is introduced.
- transformation means that DNA can be replicated as a factor outside of chromosome or by means of completion of the entire chromosome by introducing DNA as a host.
- vectors and expression control sequences do not equally function to express DNA sequences according to the present invention.
- hosts do not equally function with respect to the same expression system.
- one skilled in the art may appropriately select from a group consisting of various vectors, expression control sequences, and hosts without either departing from the scope of the present invention or bearing excessive experimental burden.
- a vector must be selected considering a host, because the vector must be replicated in the host.
- the copy number of the vector, the ability of regulating the copy number and the expression of other protein encoded by the corresponding vector should also be considered.
- sRNA system To introduce an sRNA system into a pTetlgy2glyAN vector (Korean Patent No. 1147860), genetic manipulation was performed, and to obtain a ribosome binding site that is involved in translation of the rnpA gene, inverse-PCR was performed using primers of SEQ ID NOs: 4 and 5, thereby obtaining an rnpA sRNA (SEQ ID NO: 1).
- SEQ ID NO: 4 5′-cctgggaaatgcgagcttaaccactttctgttgggccattgcattg- 3′
- SEQ ID NO: 5 5′-GCAACCATTATCACCGCCA-3
- the PCR reaction was performed using Pfu polymerase (SolGent, Korea) under the following conditions: pre-denaturation at 95° C. for 5 min, and then 28 cycles, each consisting of denaturation at 95° C. for 30 sec, annealing at 57° C. for 180 sec, and extension at 72° C. for 60 sec, followed by final extension at 72° C. for 5 min.
- Pfu polymerase SolGent, Korea
- the PCR product was electrophoresed on agarose gel to obtain a purified 5000-bp PCR product.
- the purified PCR product was incubated with the restriction enzyme DpnI (New England Biolabs, USA) for 1 hour, and then ligated with a pTetlgy2glyAN by T4 DNA ligase(Roche, Germany), and the resulting vector was transformed into E. coli dH5 ⁇ (FhuA2 lac(del)U169 phoA glnV44 ⁇ 80′ lacZ(del)M15 gyrA96 recAl relAl endAl thi-1 hsdR17, Invitrogen).
- the transformed strain was selected on an LB agar solid medium (tryptone 10 g/L, yeast extract 5 g/L, NaCl 5 g/L, and agar 15 g/L) containing 34 mg/L of chloramphenicol, thereby obtaining the recombinant plasmid pTetgly2glyAN-rnpA(sRNA) ( FIG. 1 ).
- the constructed recombinant plasmid was confirmed by cleaving with restriction enzymes and DNA sequencing.
- the plasmid pSH16a (Lee et al., Fischs and Applications of Chem. Eng., 8:3969, 2002) consisting of 16 repeats of the gene encoding the silk protein was digested with the restriction enzyme SpeI and NheI to obtain a 1.7-kb fragment. The fragment was ligated with the plasmid pSH16a digested with the restriction enzyme SpeI, thereby obtaining the recombinant plasmid pSH32. The direction of the ligated insert was determined by digestion with the restriction enzyme SpeI and NheI (New England Biolabs, USA).
- the plasmid pSH16a was digested with the restriction enzyme SpeI and NheI to obtain a 1.7-kb fragment which was then ligated with the plasmid pSH32 digested with the restriction enzyme SpeI, thereby constructing the recombinant plasmid pSH48.
- the recombinant plasmid pSH32 was digested with the restriction enzyme SpeI and NheI to obtain a 3.4-kb fragment which was then ligated with the plasmid pSH64 digested with the restriction enzyme SpeI, thereby constructing the recombinant plasmid pSH64.
- the plasmid pSH48 was digested with the restriction enzyme SpeI and NheI to obtain a 5.1-kb fragment which was then ligated with the plasmid pSH32 digested with the restriction enzyme SpeI, thereby constructing the recombinant plasmid pSH80.
- the plasmid pSH16 was digested with the restriction enzyme SpeI and NheI to obtain a 1.74-kb fragment which was then ligated with the plasmid pSH80 digested with the restriction enzyme SpeI, thereby constructing the recombinant plasmid pSH96.
- the plasmid pSH32 was digested with the restriction enzyme SpeI and NheI to obtain a 3.4-kb fragment which was then ligated with the plasmid pSH80 digested with the restriction enzyme SpeI, thereby constructing the recombinant plasmid pSH112.
- the plasmid pSH64 was digested with the restriction enzyme SpeI and NheI to obtain a 7.8-kb fragment which was then ligated with the plasmid pSH64 digested with the restriction enzyme SpeI, thereby constructing the recombinant plasmid pSH128.
- the direction of each ligated insert was determined by digestion with the restriction enzyme SpeI and NheI.
- E. coli BL21 (DE3) (F-ompT hsdSB(rB- mB-) gal dcm (DE3) a prophage carrying the T7 RNA polymerase gene) (New England Biolabs, USA) was transformed with the plasmid pTetgly2glyAN-rnpA(sRNA) obtained in Example 1 and each of the plasmid pSH16, pSH32, pSH48, pSH64, pSH80, pSH96 and pSH112 containing 16, 32, 48, 64, 80, 96 and 112 repeats of the silk protein-encoding gene, respectively.
- E. coli BL21 (DE3), transformed with the plasmid pACYC184 and each of pSH16, pSH32, pSH64, pSH96 and pSH128, was used.
- Each of the transformed strains was seeded into 10 ml of an LB liquid medium (tryptone 10 g/L, yeast extract 5 g/L, and NaCl 5 g/L)(containing 34 mg/L of chloramphenicol, 25 mg/L of kanamycin and 1% arabinose) and shake-cultured at 25° C. and 220 rpm.
- each of the strains was shake-cultured under the above-described medium conditions at 37° C. and 220 rpm.
- Example 4 Examination of the Increase in mRNA Level Caused by the Reduction in Expression of rnpA Gene by sRNA System
- E. coli BL21 (DE3) (F-ompT hsdSB(rB- mB-) gal dcm (DE3) a prophage carrying the T7 RNA polymerase gene) (New England Biolabs, USA) was transformed with the plasmid pTetgly2glyAN-rnpA(sRNA) obtained in Example 1 and pSH32.
- E. coli BL21 (DE3), transformed with the plasmid pACYC184 and pSH32, was used.
- Each of the transformed strains was seeded into 10 ml of an LB liquid medium (tryptone 10 g/L, yeast extract 5 g/L, and NaCl 5 g/L) (containing 34 mg/L of chloramphenicol, 25 mg/L of kanamycin and 1% arabinose) and shake-cultured at 25° C. and 220 rpm.
- each of the strains was shake-cultured under the above-described medium conditions at 37° C. and 220 rpm.
- RNA extraction 1 ml of Trizol was added to the cell pellet, after which the cell pellet solution was stirred for 1 minute and allowed to stand at room temperature for 5 minutes.
- chloroform in an amount equal to 20% of the total volume was added to the cell pellet solution which was then stirred for 15 seconds and centrifuged at 13,000 rpm for 15 minutes.
- the produced supernatant was transferred into a fresh tube, and the same amount of isopropanol was added thereto and carefully stirred. Then, the mixture was centrifuged at 13,000 rpm for 30 minutes, and the supernatant was discarded.
- 1 ml of 70% ethanol was added to the remaining material which was then centrifuged at 13,000 rpm for 5 minutes, and the above procedure was repeated again.
- RNA was adjusted to 500 ng, and 2 ⁇ l of dN9 primer was added thereto. Then, the reaction mixture was adjusted to a total volume of 20 ⁇ l using RNase-free distilled water. The PCR reaction was performed under the following conditions: initial annealing at 30° C. for 150 seconds, cDNA synthesis at 60° C. for 1 hour, and then heat inactivation at 95° C. for 300 seconds.
- a reaction mixture having a total volume of 20 ⁇ l contained 8 ⁇ l of RNase-free distilled water, 10 ⁇ l of SYBR Green Mastermix (Enzynomics, Korea), 1 ⁇ l of a 1/10 dilution of the cDNA, and 0.5 ⁇ l of each primer.
- the RT-PCR reaction was performed under the following conditions: initial activation at 95° C. for 10 minutes, and then 45 cycles, each consisting of denaturation at 95° C. for 30 sec, annealing at 60° C. for 30 sec, and extension at 72° C. for 30 sec. To determine the melting curve, the temperature was increased from 55° C. to 95° C. by 0.5° C., and the reaction mixture was maintained at each temperature for 5 seconds.
- a 6.6-L fermentor Bioflo 3000; New Brunswick Scientific Co.
- 1.6 L of R/2 medium 10 g/L of glucose, 0.7 g/L of MgSO 4 .7H 2 O, and an antibiotic (50 ⁇ g/mL kanamycin and/or 35 ⁇ g/mL chloramphenicol) were added to the strain in the fermentor.
- an antibiotic 50 ⁇ g/mL kanamycin and/or 35 ⁇ g/mL chloramphenicol
- air saturation was adjusted while the agitation speed was increased to 1000 rpm.
- a feeding solution was composed of 700 g/L of glucose and 20 g/L MgSO 4 .7H 2 O, and the pH of the culture was adjusted using 28% (v/v) ammonia solution.
- the OD600 reached about 70
- 1 mM IPTG was added to the culture to induce protein expression.
- the culture was sampled at 2-hour intervals.
- Cell proliferation and the concentration of the protein obtained are shown in FIG. 7 .
- the protein could be obtained at a concentration of 0.9 g/L, which was 30% higher than the previously known concentration (0.7 g/L).
- the Sortase A gene was synthesized by Bioneer (Korea), and the sfcA, cat2, CYP73A5 and CYP98A3 genes were obtained by PCR using the following primers.
- sfcA_F (SEQ ID NO: 11) 5′-CCATGGATATTCAAAAAAGAGTGAGT-3′ sfcA_R: (SEQ ID NO: 12) 5′-TCTAGATTAGATGGAGGTACGGCGGTA-3′
- Cat2_F (SEQ ID NO: 13) 5′-GAATTCATGGAGTGGGAAGAGATATATA-3′
- Cat2_R (SEQ ID NO: 14) 5′-GGTACCCTAAAATCTCTTTTTAAATTCATT-3′
- CYP73A5_F (SEQ ID NO: 15) 5′-GCGAAGCTTACAGTTCCTTGGTTTCATAA-3′
- CYP73A5_R (SEQ ID NO: 16) 5′-GTACATATGATGGACCTCCTCTTGCTGG-3′
- CYP98A3_F (SEQ ID NO: 17) 5′-GGATCCATGTCGTGGTTTCTAATAGC-3′
- CYP98A3_R (
- RnpA sRNA (SEQ ID NO: 1) and each of the sfcA, srtA and cat2 genes were inserted into pET30a (+)(Addgene, USA) and pTac15k (Addgene, USA) respectively to obtain recombinant vectors.
- Each of the vectors was transformed into an E. coli BL21 (DE3) strain.
- E. coli BL21 (DE3) strain As a control, a strain transformed with a vector obtained by inserting each of the sfcA, srtA and cat2 genes into pET30a and pTac15k was used.
- Each of the transformed strains was seeded into 10 ml of an LB liquid medium (tryptone 10 g/L, yeast extract 5 g/L, and NaCl 5 g/L) (containing 34 mg/L of chloramphenicol, 25 mg/L of kanamycin and 1% arabinose) and shake-cultured at 25° C. and 220 rpm.
- LB liquid medium tryptone 10 g/L, yeast extract 5 g/L, and NaCl 5 g/L
- each of the strains was shake-cultured under the above-described medium conditions at 37° C. and 220 rpm.
- 1 mM IPTG was added to the medium to induce expression of each protein.
- the culture was sampled and centrifuged at 4° C.
- cell pellets were dissolved in TE buffer and 5 ⁇ Laemmli sample buffer. The same amount (0.024 mg) of the sample was separated on 10% SDS-PAGE gel and stained with Coomassie brilliant blue R250 (Bio-Rad, USA) solution.
- a target protein particularly a difficult-to-express protein having a high molecular weight
- expression of a target protein can be dramatically increased by reducing expression of the rnpA gene so that the present invention is useful for increasing the productivity of proteins.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Insects & Arthropods (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
- This application is a divisional under 35 U.S.C. § 120 of U.S. patent application Ser. No. 15/533,273 filed Jun. 5, 2017, which in turn is a U.S. national phase under the provisions of 35 U.S.C. § 371 of International Patent Application No. PCT/KR2015/013419 filed Dec. 9, 2015, which in turn claims priority of Korean Patent Application No. 10-2014-0175780 filed Dec. 9, 2014 and Korean Patent Application No. 10-2015-0174828 filed Dec. 9, 2015. The disclosures of U.S. patent application Ser. No. 15/533,273, International Patent Application No. PCT/KR2015/013419, Korean Patent Application No. 10-2014-0175780, and Korean Patent Application No. 10-2015-0174828 are hereby incorporated herein by reference in their respective entireties, for all purposes.
- The present invention relates to a method for improving the production of a recombinant protein in a recombinant microorganism, and more particularly to a method for improving the production of a recombinant protein by use of a recombinant microorganism into which a gene encoding a target protein and an sRNA against a gene encoding ribonuclease P are introduced.
- The development of genetic manipulation technology has led to many studies focused on producing large amounts of useful proteins using bacterial and a variety of animals and plants. Host cells for producing large amounts of useful proteins are present, including bacteria such as E. coli, and yeasts such as P. pastoris. Of these host cells, E. coli has been most widely used, and studies thereon have been most frequently conducted (Choi et al., Chem. Eng. Sci., 66: 876, 2006; Lee, Trends Biotechnol., 14:98, 1996).
- However, if the useful protein to be produced is larger in size than a naturally occurring protein or is difficult to express, many problems may arise. If the size of a protein is large, translation of the protein may be difficult due to lack of messanger RNA (mRNA), and thus expression of the desired full-length protein may be difficult. In addition, a recombinant protein that is not naturally present in E. coli may be difficult to express, due to proteolysis and RNase-induced degradation of mRNA (GoBringer et al., J Bacteriol., 188: 6816, 2006; Olson et al., PLoS Pathog., 7(2): e1001287, 2011; Jung et al., Biochem Biophys Res Commun., 186(3):1463, 1992; Altman et al., Phil Trans R Soc., 366, 2011; Turrini et al., PLos One., 7(3): e32456, 2012).
- Accordingly, the present inventors have made extensive efforts to develop a protein expression system for increasing the production of a difficult-to-express foreign protein, and as a result, have found that, when expression of the rnpA gene (which is a component of ribonuclease P) in a process of expressing the foreign protein by introducing a gene encoding the foreign protein is reduced, expression of the difficult-to-express foreign protein increases, thereby completing the present invention.
- It is a main object of the present invention to provide a recombinant microorganism into which a gene encoding a target protein and an sRNA against a gene encoding Ribonuclease P are introduced to increase the production of a difficult-to-express foreign protein.
- Another object of the present invention is to provide a method for producing a target protein by culturing the above-described recombinant microorganism.
- To achieve the above objects, the present invention provides a recombinant vector for expressing a target protein, which comprises a gene encoding the target protein and an sRNA against a gene encoding ribonuclease P, and a recombinant microorganism into which the recombinant vector is introduced.
- The present invention also provides a recombinant microorganism into which a gene encoding a target protein and an sRNA against a gene encoding ribonuclease P are introduced.
- The present invention also provides a method for producing a target protein, the method comprising the steps of: (a) producing the target protein by culturing the above-described recombinant microorganism and inducing expression of the target protein in the recombinant microorganism; and (b) recovering the produced target protein.
- The present invention also provides a method for producing a target protein, comprising the steps of: expressing and producing the target protein by culturing a recombinant microorganism into which a gene encoding the target protein is introduced; and recovering the produced target protein, wherein expression of ribonuclease P is reduced to increase expression of the target protein.
- The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
-
FIG. 1 is a gene map of the plasmid pTetly2glyAN-rnpA(sRNA). -
FIG. 2 shows the results of analyzing expression levels of a silk protein consisting of 16 repeats and a silk protein consisting of 32 repeats by SDS-PAGE. (lane 1: a marker showing protein standard molecular weight;lanes 2 and 3: the results of inducing protein expression in a stain transformed with the plasmid pSH16 at an OD600 of 0.4;lanes 4 and 5: the results of inducing protein expression in a strain transformed with the plasmid pSH16 and pACYC184-rnpA(sRNA) at an OD600 of 0.4; lanes 6 and 7: the results of inducing protein expression in a strain transformed with the plasmid pSH32 at an OD600 of 0.4; and lanes 8 and 9: the results of inducing protein expression in a strain transformed with the plasmid pSH32 and pACYC184-rnpA(sRNA) at an OD600 of 0.4.) -
FIG. 3 shows the results of analyzing expression levels of a silk protein consisting of 64 repeats by SDS-PAGE. (lane 1: a marker showing protein standard molecular weight; lane 2: the result of inducing protein expression in a strain transformed with pSH64 at an OD600 of 0.4; and lane 3: the result of inducing protein expression in a strain transformed with the plasmid pSH64 and pACYC184-rnpA(sRNA) at an OD600 of 0.4.) -
FIG. 4A shows the results of analyzing expression levels of a silk protein consisting of 96 repeats by SDS-PAGE. (lane 1: a marker showing protein standard molecular weight; lane 2: the result of inducing protein expression in a strain transformed with pSH96 at an OD600 of 0.4; and lane 3: the result of inducing protein expression in a strain transformed with the plasmid pSH96 and pACYC184-rnpA(sRNA) at an OD600 of 0.4.) -
FIG. 4B shows the results obtained by inducing protein expression in strains transformed with the plasmid pSH96 and the plasmid pSH96 plus pTetgly2glyAN-rnpA(sRNA), respectively, at an OD600 of 0.4, analyzing protein expression levels by SDS-PAGE, quantifying the protein expression levels using a densitometer, and then averaging the protein expression levels. -
FIG. 5 shows the result of analyzing expression levels of a silk protein consisting of 128 repeats by SDS-PAGE. (lane 1: a marker showing protein standard molecular weight; lane 2: the result of inducing protein expression in a strain transformed with pSH128 at an OD600 of 0.4; and lane 3: the result of inducing protein expression in a strain transformed with pSH128 and pACYC184-rnpA(sRNA) at an OD600 of 0.4.) -
FIG. 6 is a graph showing the results of examining whether the level of intracellular mRNA is increased by reducing expression of the rnpA gene. -
FIG. 7A is a graph showing the amount of a silk protein consisting of 96 repeats, produced by fed-batch culture, andFIG. 7B shows the results of electrophoresis of the protein. -
FIG. 8 shows the results of electrophoresis performed using a system for reducing expression of the rnpA gene according to the present invention in order to confirm increased expressions of difficult-to-express proteins other than the silk protein. Specifically, electrophoresis image (a) shows the results of analyzing the expression level of malic enzyme (SfcA) by SDS-PAGE. (lane 1: a marker showing protein standard molecular weight; lane 2: the result of inducing protein expression in non-transformed BL21(DE3);lanes 3 and 4: the results of inducing protein expression in a strain transformed with SfcA at an OD600 of 0.4; andlanes 5 and 6: the results of inducing protein expression in a strain transformed with SfcA and rnpA(sRNA) at an OD600 of 0.4). Electrophoresis image (b) shows the results of analyzing the expression level of Cat2 by SDS-PAGE. (lane 1: a marker showing protein standard molecular weight;lanes 2 and 3: the results of inducing protein expression in a strain transformed with Cat2 at an OD600 of 0.4; andlanes 4 and 5: the results of inducing protein expression in a strain transformed with Cat2-rnpA(sRNA) at an OD600 of 0.4). Electrophoresis image (c) shows the results of analyzing the expression level of SrtA by SDS-PAGE. (lane 1: a marker showing protein standard molecular weight;lanes 2 and 3: the results of inducing protein expression in a strain transformed with SrtA at an OD600 of 0.4; andlanes 4 and 5: the results of inducing protein expression in a strain transformed with srtA-rnpA(sRNA) at an OD600 of 0.4). Electrophoresis image (d) shows the results of analyzing the expression level of CYP73A5 by SDS-PAGE. (lane 1: a marker showing protein standard molecular weight;lanes 2 and 3: the results of inducing protein expression in a strain transformed with CYP73A5at an OD600 of 0.4; andlanes 4 and 5: the results of inducing protein expression in a strain transformed with CYP73A5-rnpA(sRNA) at an OD600 of 0.4). Electrophoresis image (e) shows the results of analyzing the expression level of CYP98A3 by SDS-PAGE. (lane 1: a marker showing protein standard molecular weight;lanes 2 and 3: the results of inducing protein expression in a strain transformed with CYP98A3 at an OD600 of 0.4; andlanes 4 and 5: the results of inducing protein expression in a strain transformed with CYP98A3-rnpA(sRNA) at an OD600 of 0.4). - The present inventors have developed a method for improving expression of a difficult-to-express recombinant protein, which was not easily produced in the prior art, in a recombinant microorganism by reducing expression of ribonuclease P to increase the mRNA level of a useful protein in cells.
- In the present invention, expression of the rnpA gene that is a component of ribonuclease P was reduced using a sRNA system comprising sRNA, and as a result, it was shown that expression of a high-molecular-weight silk protein that is a difficult-to-express protein was increased dramatically.
- As used herein, the term “difficult-to-express protein” refers to a protein having a molecular weight of 50 kDa or more.
- Therefore, in one aspect, the present invention is directed to a recombinant vector for expressing a target protein, which comprises a gene encoding the target protein and an sRNA against a gene encoding ribonuclease P, and to a recombinant microorganism transformed with the recombinant vector.
- In the present invention, the target protein may be a protein selected from among difficult-to-express proteins silk proteins, antibodies, enzymes, cytochromes, and sortase A, but is not limited thereto.
- In the present invention, the sRNA may be an sRNA against an rnpA gene, and may have a nucleotide sequence set forth in any one of SEQ ID NOs: 1 to 3, but is not limited thereto as long as it reduces the expression of an rnpA gene.
- In the present invention, examples of microorganisms for production of proteins that can be used may include Escherichia, Pseudomonas, Saccharomyces, and the like, and may be preferably an Escherichia microorganism, most preferably E. coli. In particular, it is advantageous that E. coli can be easily industrialized since genetic information and culture conditions that are widely used industrially are very well known.
- In an example of the present invention, a recombinant E. coli strain was constructed by transformation with a gene encoding a silk protein resulting from modification of a dragline silk protein obtained from Nephila clavipes, a nucleotide sequence encoding glycine tRNA, and an sRNA for reducing expression of the RnpA that is a component of ribonuclease P. The constructed recombinant E. coli strain was cultured. As a result, it could be seen that the protein of the silk protein increased 3-fold or more. In addition, it was shown that expression of a silk protein consisting of 16, 32, 48, 64, 80, 96, 112 and 128 repeats of a specific amino acid sequence (SGRGGLGGTGAGMAAAAAMGGAGQGGYGGLGSQG) (SEQ ID NO: 19) was dramatically increased by reducing expression of the rnpA gene that is a component of ribonuclease P. Furthermore, it was shown that expressions of eGFP, SfcA and a full-length IgG antibody were also dramatically increased by reducing expression of the rnpA gene that is a component of ribonuclease P.
- In view of the results indicating that the production of a long recombinant protein or a difficult-to-express protein is increased by reducing expression of the rnpA gene that is a component of ribonuclease P, it will be obvious to those skilled in the art that the degradation of messenger RNA (mRNA) has a great influence on protein expression and that overexpression of a target protein can be effectively achieved by reducing expression of a gene associated with messenger RNA (mRNA) degradation.
- In another example of the present invention, the expressions of a malic enzyme-encoding gene (sfcA), a sortase A-encoding gene (srtA), a 4-hydroxybutyrate coenzyme A transferase-encoding gene (Cat2) and the cytochrome P450 gene (CYP73A5; cinnamate 4-hydrosylase and CYP98A3) were examined using the system for reducing expression of the rnpA gene according to the present invention. As a result, it was shown that a strain expressing an sRNA against the rnpA gene together with the gene encoding each of the proteins showed a higher protein expression level compared to a strain expressing no sRNA (
FIG. 8 ; see electrophoresis images (a) through (e)). - In another aspect, the present invention is directed to a recombinant microorganism into which a gene encoding a target protein and an sRNA against a gene encoding ribonuclease P are introduced.
- In the present invention, the gene encoding the target protein and the sRNA against the gene encoding ribonuclease P may be present in the respective vectors or may be incorporated into the microbial chromosome.
- In still another aspect, the present invention is directed to a method for producing a difficult-to-express target protein, the method comprising the steps of: (a) producing the target protein by culturing the recombinant microorganism and inducing expression of the target protein in the recombinant microorganism; and (b) recovering the produced target protein.
- In an example of the present invention, a recombinant E. coli strain was constructed by transformation with a gene encoding a silk protein, a nucleotide sequence encoding glycine tRNA, and an sRNA for reducing expression of the rnpA gene that is a component of ribonuclease P. The constructed recombinant E. coli strain was cultured. As a result, it could be seen that the protein of the silk protein increased 3-fold or more.
- In another example of the present invention, it was shown that, when a gene encoding eGFP protein, a gene encoding sfcA protein and a gene encoding a full-length IgG antibody protein were co-expressed with an sRNA against the rnpA gene, expressions of the proteins increased.
- In the present invention, preferably, the target protein may be a large protein having a molecular weight of 50 kDa or more as a difficult-to-express protein. For example, the target protein may be a protein selected from a group consisting of silk proteins, antibodies, enzymes, cytochromes, and sortase A, but is not limited thereto.
- In still another aspect, the present invention is directed to a method for producing a target protein, comprising the steps of: expressing and producing the target protein by culturing a recombinant microorganism into which a gene encoding the target protein is introduced; and recovering the produced target protein, wherein expression of ribonuclease P in the recombinant microorganism is reduced to increase expression of the target protein.
- In the present invention, the target protein may be a difficult-to-express protein or a protein having a molecular weight of 50 kDa or more, and a substance of inhibiting the expression of ribonuclease P may be added.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Generally, the nomenclature used herein and the experiment methods, which will be described below, are those well known and commonly employed in the art.
- The definition of main terms used in the detailed description of the invention is as follows.
- As used herein, the term “sRNA (small RNA)” refers to a short-length RNA, which is usually 200 or less nucleotides in length, which is not translated into protein and effectively inhibits the translation of a specific mRNA by complementary binding.
- As used herein, the term “ribosome binding site” refers to a site where ribosome binds to mRNA for the transcription of the mRNA.
- As used herein, the term “gene” is intended to have the broadest meaning, and the gene can encode a structural protein or a regulatory protein. Herein, the regulatory protein includes a transcriptional factor, a heat shock protein, or a protein that is involved in DNA/RNA replication, transcription and/or translation. Also, the target gene whose expression is to be inhibited may be present as an extrachromosomal element.
- As used herein, the term “vector” means a DNA construct containing a DNA sequence operably linked to a suitable control sequence capable of effecting the expression of the DNA in a suitable host. The vector may be a plasmid, a phage particle, or simply a potential genomic insert. Once incorporated into a suitable host, the vector may replicate and function independently of the host genome, or may in some instances, integrate into the genome itself. In the present specification, “plasmid” and “vector” are sometimes used interchangeably, as the plasmid is the most commonly used form of vector. For the purpose of the present invention, the plasmid vector is preferably used. A typical plasmid vector which can be used for this purpose contains: (a) a replication origin by which replication occurs efficiently such that several hundred plasmid vectors per host cell are created; (b) an antibiotic-resistant gene by which host cells transformed with the plasmid vector can be selected; and (c) restriction enzyme cutting sites into which foreign DNA fragments can be inserted. Even if suitable restriction enzyme cutting sites are not present in the vector, the use of a conventional synthetic oligonucleotide adaptor or linker enables the easy ligation between the vector and the foreign DNA fragments. After ligation, the vector should be transformed into suitable host cells. The transformation can be easily achieved by the calcium chloride method or electroporation (Neumann, et al., EMBO J., 1:841, 1982). A publicly known expression vector in the art may be used as a vector for expressing sRNA according to the present invention.
- A nucleic acid sequence is operably linked when it is placed into arranged in a functional relationship with another nucleic acid sequence. The nucleotide sequence may be a gene and a control sequence(s) linked to be capable of expressing the gene when a suitable molecule binds to a control sequence(s) (e.g., transcription-activating protein). For example, DNA for a pre-sequence or a secretory leader is operably linked to a DNA encoding a polypeptide when expressed as a pre-protein participating in secretion of the polypeptide; a promoter or an enhancer is operably linked to a coding sequence when affecting the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence when affecting the transcription of the sequence, or to a coding sequence when arranged to facilitate translation. Generally, the term “operably linked” means that the DNA linked sequences are contiguous, and in the case of the secretory leader, are contiguous and present in a reading frame. However, an enhancer is not necessarily contiguous. The linkage between these sequences is performed by ligation at a convenient restriction enzyme site. However, when this site does not exist, a synthetic oligonucleotide adaptor or a linker is used according to a conventional method.
- In addition, the present invention is directed to a recombinant microorganism into which an expression vector comprising a nucleic acid encoding the sRNA is introduced. As used herein, the term “transformation” means that DNA can be replicated as a factor outside of chromosome or by means of completion of the entire chromosome by introducing DNA as a host.
- Of course, it should be understood that all vectors and expression control sequences do not equally function to express DNA sequences according to the present invention. Similarly, all hosts do not equally function with respect to the same expression system. However, one skilled in the art may appropriately select from a group consisting of various vectors, expression control sequences, and hosts without either departing from the scope of the present invention or bearing excessive experimental burden. For example, a vector must be selected considering a host, because the vector must be replicated in the host. Specifically, the copy number of the vector, the ability of regulating the copy number and the expression of other protein encoded by the corresponding vector (e.g., the expression of an antibiotic marker) should also be considered.
- Hereinafter, the present invention will be described in further detail with reference to examples. It will be obvious to a person having ordinary skill in the art that these examples are for illustrative purposes only and are not to be construed to limit the scope of the present invention.
- All procedures for gene manipulation followed standardized methods (Sambrook et al., Molecular cloning: a laboratory manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989).
- To introduce an sRNA system into a pTetlgy2glyAN vector (Korean Patent No. 1147860), genetic manipulation was performed, and to obtain a ribosome binding site that is involved in translation of the rnpA gene, inverse-PCR was performed using primers of SEQ ID NOs: 4 and 5, thereby obtaining an rnpA sRNA (SEQ ID NO: 1).
-
SEQ ID NO: 4: 5′-cctgggaaatgcgagcttaaccactttctgttgggccattgcattg- 3′ SEQ ID NO: 5: 5′-GCAACCATTATCACCGCCA-3 - The PCR reaction was performed using Pfu polymerase (SolGent, Korea) under the following conditions: pre-denaturation at 95° C. for 5 min, and then 28 cycles, each consisting of denaturation at 95° C. for 30 sec, annealing at 57° C. for 180 sec, and extension at 72° C. for 60 sec, followed by final extension at 72° C. for 5 min.
- The PCR product was electrophoresed on agarose gel to obtain a purified 5000-bp PCR product. The purified PCR product was incubated with the restriction enzyme DpnI (New England Biolabs, USA) for 1 hour, and then ligated with a pTetlgy2glyAN by T4 DNA ligase(Roche, Germany), and the resulting vector was transformed into E. coli dH5α (FhuA2 lac(del)U169 phoA glnV44 Φ80′ lacZ(del)M15 gyrA96 recAl relAl endAl thi-1 hsdR17, Invitrogen).
- The transformed strain was selected on an LB agar solid medium (tryptone 10 g/L, yeast extract 5 g/L, NaCl 5 g/L, and agar 15 g/L) containing 34 mg/L of chloramphenicol, thereby obtaining the recombinant plasmid pTetgly2glyAN-rnpA(sRNA) (
FIG. 1 ). The constructed recombinant plasmid was confirmed by cleaving with restriction enzymes and DNA sequencing. - In order to construct a recombinant plasmid containing 32 repeats of a gene that encodes a silk protein resulting from modification of a Nephila clavipes derived dragline silk protein that is a difficult-to-express protein having a large size, the plasmid pSH16a (Lee et al., Theories and Applications of Chem. Eng., 8:3969, 2002) consisting of 16 repeats of the gene encoding the silk protein was digested with the restriction enzyme SpeI and NheI to obtain a 1.7-kb fragment. The fragment was ligated with the plasmid pSH16a digested with the restriction enzyme SpeI, thereby obtaining the recombinant plasmid pSH32. The direction of the ligated insert was determined by digestion with the restriction enzyme SpeI and NheI (New England Biolabs, USA).
- Similarly, the plasmid pSH16a was digested with the restriction enzyme SpeI and NheI to obtain a 1.7-kb fragment which was then ligated with the plasmid pSH32 digested with the restriction enzyme SpeI, thereby constructing the recombinant plasmid pSH48. The recombinant plasmid pSH32 was digested with the restriction enzyme SpeI and NheI to obtain a 3.4-kb fragment which was then ligated with the plasmid pSH64 digested with the restriction enzyme SpeI, thereby constructing the recombinant plasmid pSH64. The plasmid pSH48 was digested with the restriction enzyme SpeI and NheI to obtain a 5.1-kb fragment which was then ligated with the plasmid pSH32 digested with the restriction enzyme SpeI, thereby constructing the recombinant plasmid pSH80. The plasmid pSH16 was digested with the restriction enzyme SpeI and NheI to obtain a 1.74-kb fragment which was then ligated with the plasmid pSH80 digested with the restriction enzyme SpeI, thereby constructing the recombinant plasmid pSH96. The plasmid pSH32 was digested with the restriction enzyme SpeI and NheI to obtain a 3.4-kb fragment which was then ligated with the plasmid pSH80 digested with the restriction enzyme SpeI, thereby constructing the recombinant plasmid pSH112. The plasmid pSH64 was digested with the restriction enzyme SpeI and NheI to obtain a 7.8-kb fragment which was then ligated with the plasmid pSH64 digested with the restriction enzyme SpeI, thereby constructing the recombinant plasmid pSH128. The direction of each ligated insert was determined by digestion with the restriction enzyme SpeI and NheI.
- In order to examine the effect of co-overexpressing the glycine tRNA gene and reducing the expression of the ribonuclease P (rnpA) gene by use of the sRNA system in silk protein production, E. coli BL21 (DE3) (F-ompT hsdSB(rB- mB-) gal dcm (DE3) a prophage carrying the T7 RNA polymerase gene) (New England Biolabs, USA) was transformed with the plasmid pTetgly2glyAN-rnpA(sRNA) obtained in Example 1 and each of the plasmid pSH16, pSH32, pSH48, pSH64, pSH80, pSH96 and pSH112 containing 16, 32, 48, 64, 80, 96 and 112 repeats of the silk protein-encoding gene, respectively.
- As a control, E. coli BL21 (DE3), transformed with the plasmid pACYC184 and each of pSH16, pSH32, pSH64, pSH96 and pSH128, was used. Each of the transformed strains was seeded into 10 ml of an LB liquid medium (tryptone 10 g/L, yeast extract 5 g/L, and NaCl 5 g/L)(containing 34 mg/L of chloramphenicol, 25 mg/L of kanamycin and 1% arabinose) and shake-cultured at 25° C. and 220 rpm. Next, each of the strains was shake-cultured under the above-described medium conditions at 37° C. and 220 rpm. When the culture reached an OD600 of 0.4, 1 mM IPTG was added to the medium to induce expression of the silk protein gene. At 4 hours after induction of the expression, the culture was sampled and centrifuged at 4° C. and 10,000 g for 10 minutes, and the obtained cell pellets were dissolved in TE buffer and 5× Laemmli sample buffer. The same amount (0.024 mg) of the sample was separated using 10% SDS-PAGE gel, after which it was stained with Coomassie brilliant blue R250 (Bio-Rad, USA) solution and quantified using the GS-710 Calibrated Imaging Densitometer (Bio-Rad, USA) (see
FIGS. 2, 3, 4A, and 4B ). - Furthermore, expression of the strain transformed with the plasmid pSH96 and pTetgly2glyAN-rnpA(sRNA) was induced at an OD600 0.4, after which protein expression was analyzed by SDS-PAGE, quantified using a densitometer and averaged. The results are shown in
FIG. 4B . In addition, the results of expression performed using the plasmid pSH128 are shown inFIG. 5 . - As a result, it could be seen that, due to the reduction in expression of ribonuclease P (RnpA), expression of the silk protein consisting of 16 repeats was increased by about 150% compared to the control, and expression of the silk protein consisting of 32 repeats was increased by about 300% compared to the control. Furthermore, expression of the silk protein consisting of 48 repeats was increased by about 300%, and expression of the silk protein consisting of 64 repeats was increased by about 300%. In addition, expression of the silk protein consisting of 80 repeats was increased by about 300%, expression of the silk protein consisting of 112 repeats was increased by about 200%, and expression of the silk protein consisting of 128 repeats was increased by about 150%.
- In this Example, in order to prevent the degradation of messenger RNA in the production of recombinant, difficult-to-express and useful proteins, expression of the rnpA gene that is a component of ribonuclease P was reduced by introduction of the sRNA system. In addition, whether the level of intracellular mRNA would be increased by the reduction in expression of the rnpA gene was examined.
- Specifically, E. coli BL21 (DE3) (F-ompT hsdSB(rB- mB-) gal dcm (DE3) a prophage carrying the T7 RNA polymerase gene) (New England Biolabs, USA) was transformed with the plasmid pTetgly2glyAN-rnpA(sRNA) obtained in Example 1 and pSH32.
- As a control, E. coli BL21 (DE3), transformed with the plasmid pACYC184 and pSH32, was used. Each of the transformed strains was seeded into 10 ml of an LB liquid medium (tryptone 10 g/L, yeast extract 5 g/L, and NaCl 5 g/L) (containing 34 mg/L of chloramphenicol, 25 mg/L of kanamycin and 1% arabinose) and shake-cultured at 25° C. and 220 rpm. Next, each of the strains was shake-cultured under the above-described medium conditions at 37° C. and 220 rpm. When the culture reached an OD600 of 0.4, 1 mM IPTG was added to the medium to induce expression of the silk protein gene. At 4 hours after induction of the expression, the culture was sampled and centrifuged at 4° C. and 10,000 g for 10 minutes to obtain cell pellets, and RNA was extracted from the cell pellets.
- For RNA extraction, 1 ml of Trizol was added to the cell pellet, after which the cell pellet solution was stirred for 1 minute and allowed to stand at room temperature for 5 minutes. Next, chloroform in an amount equal to 20% of the total volume was added to the cell pellet solution which was then stirred for 15 seconds and centrifuged at 13,000 rpm for 15 minutes. The produced supernatant was transferred into a fresh tube, and the same amount of isopropanol was added thereto and carefully stirred. Then, the mixture was centrifuged at 13,000 rpm for 30 minutes, and the supernatant was discarded. Next, 1 ml of 70% ethanol was added to the remaining material which was then centrifuged at 13,000 rpm for 5 minutes, and the above procedure was repeated again. Next, the resulting material was dried at room temperature and dissolved in 30 μl of RNase-free distilled water. In order to replace the extracted RNA with complementary DNA (cDNA), qPCR was performed using Rocketstrip (Bioneer, Korea). The extracted RNA was adjusted to 500 ng, and 2 μl of dN9 primer was added thereto. Then, the reaction mixture was adjusted to a total volume of 20 μl using RNase-free distilled water. The PCR reaction was performed under the following conditions: initial annealing at 30° C. for 150 seconds, cDNA synthesis at 60° C. for 1 hour, and then heat inactivation at 95° C. for 300 seconds.
- To perform RT-PCR using the prepared cDNA, a reaction mixture having a total volume of 20 μl contained 8 μl of RNase-free distilled water, 10 μl of SYBR Green Mastermix (Enzynomics, Korea), 1 μl of a 1/10 dilution of the cDNA, and 0.5 μl of each primer. The RT-PCR reaction was performed under the following conditions: initial activation at 95° C. for 10 minutes, and then 45 cycles, each consisting of denaturation at 95° C. for 30 sec, annealing at 60° C. for 30 sec, and extension at 72° C. for 30 sec. To determine the melting curve, the temperature was increased from 55° C. to 95° C. by 0.5° C., and the reaction mixture was maintained at each temperature for 5 seconds.
- As a result, as shown in
FIG. 6 , in the case of cells in which expression of ribonuclease P (RnpA) was reduced, the level of mRNA was 24-fold higher than that in the control. This suggests that the degradation of mRNA is prevented by reducing expression of ribonuclease P (RnpA). - The strain transformed with the plasmid pSH96 and pACYC184-rnpA(sRNA), constructed in Example 3, was cultured by fed-batch fermentation, and an increase in protein production in the strain was examined.
- For fed-batch fermentation, a 6.6-L fermentor (Bioflo 3000; New Brunswick Scientific Co.) was used, and 1.6 L of R/2 medium, 10 g/L of glucose, 0.7 g/L of MgSO4.7H2O, and an antibiotic (50 μg/mL kanamycin and/or 35 μg/mL chloramphenicol) were added to the strain in the fermentor. To adjust the dissolved oxygen level to 40%, air saturation was adjusted while the agitation speed was increased to 1000 rpm. A feeding solution was composed of 700 g/L of glucose and 20 g/L MgSO4.7H2O, and the pH of the culture was adjusted using 28% (v/v) ammonia solution. When the OD600 reached about 70, 1 mM IPTG was added to the culture to induce protein expression. For 8 hours after induction of the expression, the culture was sampled at 2-hour intervals. Cell proliferation and the concentration of the protein obtained are shown in
FIG. 7 . As can be seen inFIG. 7 , the protein could be obtained at a concentration of 0.9 g/L, which was 30% higher than the previously known concentration (0.7 g/L). - Using the system for reducing rnpA gene expression according to the present invention, expressions of the gene (sfcA, SEQ ID NO: 6) encoding malic enzyme, the gene (srtA, SEQ ID NO: 7) encoding sortase A, the gene (cat2, SEQ ID NO: 8) encoding 4-hydroxybutyrate coenzyme A transferase and the cytochrome P450 gene (CYP73A5; cinnamate 4-hydrosylase:SEQ ID NO: 9 and CYP98A3:SEQ ID NO: 10) were analyzed, in addition to expression of the gene encoding silk protein. The Sortase A gene was synthesized by Bioneer (Korea), and the sfcA, cat2, CYP73A5 and CYP98A3 genes were obtained by PCR using the following primers.
-
sfcA_F: (SEQ ID NO: 11) 5′-CCATGGATATTCAAAAAAGAGTGAGT-3′ sfcA_R: (SEQ ID NO: 12) 5′-TCTAGATTAGATGGAGGTACGGCGGTA-3′ Cat2_F: (SEQ ID NO: 13) 5′-GAATTCATGGAGTGGGAAGAGATATATA-3′ Cat2_R: (SEQ ID NO: 14) 5′-GGTACCCTAAAATCTCTTTTTAAATTCATT-3′ CYP73A5_F: (SEQ ID NO: 15) 5′-GCGAAGCTTACAGTTCCTTGGTTTCATAA-3′ CYP73A5_R: (SEQ ID NO: 16) 5′-GTACATATGATGGACCTCCTCTTGCTGG-3′ CYP98A3_F: (SEQ ID NO: 17) 5′-GGATCCATGTCGTGGTTTCTAATAGC-3′ CYP98A3_R: (SEQ ID NO: 18) 5′-GAATTCTTACATATCGTAAGGCACGC-3′ - RnpA sRNA (SEQ ID NO: 1) and each of the sfcA, srtA and cat2 genes were inserted into pET30a (+)(Addgene, USA) and pTac15k (Addgene, USA) respectively to obtain recombinant vectors. Each of the vectors was transformed into an E. coli BL21 (DE3) strain. As a control, a strain transformed with a vector obtained by inserting each of the sfcA, srtA and cat2 genes into pET30a and pTac15k was used.
- Each of the transformed strains was seeded into 10 ml of an LB liquid medium (tryptone 10 g/L, yeast extract 5 g/L, and NaCl 5 g/L) (containing 34 mg/L of chloramphenicol, 25 mg/L of kanamycin and 1% arabinose) and shake-cultured at 25° C. and 220 rpm. Next, each of the strains was shake-cultured under the above-described medium conditions at 37° C. and 220 rpm. When the culture reached an OD600 of 0.4, 1 mM IPTG was added to the medium to induce expression of each protein. At 4 hours after induction of the expression, the culture was sampled and centrifuged at 4° C. and 10,000 g for 10 minutes to obtain cell pellets. The cell pellets were dissolved in TE buffer and 5× Laemmli sample buffer. The same amount (0.024 mg) of the sample was separated on 10% SDS-PAGE gel and stained with Coomassie brilliant blue R250 (Bio-Rad, USA) solution.
- As a result, as can be seen in
FIG. 8 (see electrophoresis images (a) through (e) therein), the expression levels of malic enzyme, sortase A, 4-hydroxybutyrate coenzyme A transferase (Cat2) and cytochrome P450 (cinnamate 4-hydrosylase and CYP98A3), expressed together with the RnpA sRNA, were significantly higher than the expression levels of the proteins expressed in the absence of the RnpA sRNA. - Although the present invention has been described in detail with reference to the specific features, it will be apparent to those skilled in the art that this description is only for a preferred embodiment and does not limit the scope of the present invention. Thus, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.
- According to the present invention, expression of a target protein, particularly a difficult-to-express protein having a high molecular weight can be dramatically increased by reducing expression of the rnpA gene so that the present invention is useful for increasing the productivity of proteins.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/027,478 US20180327801A1 (en) | 2014-12-09 | 2018-07-05 | METHOD FOR PREPARING RECOMBINANT PROTEINS THROUGH REDUCTION OF rnpA GENE EXPRESSION |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20140175780 | 2014-12-09 | ||
KR10-2014-0175780 | 2014-12-09 | ||
PCT/KR2015/013419 WO2016093606A1 (en) | 2014-12-09 | 2015-12-09 | Method for preparing recombinant proteins through reduction of rnpa gene expression |
KR1020150174828A KR101765255B1 (en) | 2014-12-09 | 2015-12-09 | Method for Preparing Recombinant Proteins Through Reduced Expression of rnpA |
KR10-2015-0174828 | 2015-12-09 | ||
US201715533273A | 2017-06-05 | 2017-06-05 | |
US16/027,478 US20180327801A1 (en) | 2014-12-09 | 2018-07-05 | METHOD FOR PREPARING RECOMBINANT PROTEINS THROUGH REDUCTION OF rnpA GENE EXPRESSION |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2015/013419 Division WO2016093606A1 (en) | 2014-12-09 | 2015-12-09 | Method for preparing recombinant proteins through reduction of rnpa gene expression |
US15/533,273 Division US10351890B2 (en) | 2014-12-09 | 2015-12-09 | Method for preparing recombinant proteins through reduction of rnpA gene expression |
Publications (1)
Publication Number | Publication Date |
---|---|
US20180327801A1 true US20180327801A1 (en) | 2018-11-15 |
Family
ID=56344018
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/533,273 Active US10351890B2 (en) | 2014-12-09 | 2015-12-09 | Method for preparing recombinant proteins through reduction of rnpA gene expression |
US16/027,478 Abandoned US20180327801A1 (en) | 2014-12-09 | 2018-07-05 | METHOD FOR PREPARING RECOMBINANT PROTEINS THROUGH REDUCTION OF rnpA GENE EXPRESSION |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/533,273 Active US10351890B2 (en) | 2014-12-09 | 2015-12-09 | Method for preparing recombinant proteins through reduction of rnpA gene expression |
Country Status (3)
Country | Link |
---|---|
US (2) | US10351890B2 (en) |
KR (1) | KR101765255B1 (en) |
CN (1) | CN107208106B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107881156A (en) * | 2017-11-21 | 2018-04-06 | 上海海洋大学 | Express GCRV spike protein VP56 recombinant baculovirus and application |
KR102363366B1 (en) * | 2018-11-23 | 2022-02-16 | (주)메디코스바이오텍 | Composition for Treating Alopecia or Stimulating Hair Growth |
KR102488022B1 (en) * | 2020-12-07 | 2023-01-13 | (주)메디코스바이오텍 | Recombinant Microorganism Having Enhanced Ability to Produce Recombinant Silk Protein and Method for Producing High Molecular Weight Recombinant Silk Protein Using The Same |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2335389A1 (en) | 2000-03-01 | 2001-09-01 | Message Pharmaceuticals, Inc. | Novel bacterial rnase p proteins and their use in identifying antibacterial compounds |
KR101147860B1 (en) | 2008-09-22 | 2012-05-25 | 한국과학기술원 | Method for Preparing Protein Having High Specific Amino Acid Content Through Co-expression of tRNA of Specific Amino Acid |
US9089545B2 (en) | 2011-01-26 | 2015-07-28 | University Of Rochester | Small molecule RNase inhibitors and methods of use |
EP2803727B1 (en) * | 2012-01-11 | 2018-11-07 | Korea Advanced Institute Of Science And Technology | Synthesis-regulating srna and method for preparing same |
-
2015
- 2015-12-09 CN CN201580072797.9A patent/CN107208106B/en active Active
- 2015-12-09 KR KR1020150174828A patent/KR101765255B1/en active Active
- 2015-12-09 US US15/533,273 patent/US10351890B2/en active Active
-
2018
- 2018-07-05 US US16/027,478 patent/US20180327801A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN107208106B (en) | 2025-05-13 |
US20170342454A1 (en) | 2017-11-30 |
KR20160070028A (en) | 2016-06-17 |
KR101765255B1 (en) | 2017-08-04 |
US10351890B2 (en) | 2019-07-16 |
CN107208106A (en) | 2017-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yim et al. | Isolation of fully synthetic promoters for high‐level gene expression in Corynebacterium glutamicum | |
Opdyke et al. | RNase III participates in GadY-dependent cleavage of the gadX-gadW mRNA | |
Phan et al. | Development of P grac 100-based expression vectors allowing high protein production levels in Bacillus subtilis and relatively low basal expression in Escherichia coli | |
US20230287439A1 (en) | Pathway integration and expression in host cells | |
Aw et al. | Liquid PTVA: a faster and cheaper alternative for generating multi-copy clones in Pichia pastoris | |
CN108949869B (en) | Carbon-source-free repression pichia pastoris expression system, and establishment method and application thereof | |
US20180327801A1 (en) | METHOD FOR PREPARING RECOMBINANT PROTEINS THROUGH REDUCTION OF rnpA GENE EXPRESSION | |
Gao et al. | Three novel Escherichia coli vectors for convenient and efficient molecular biological manipulations | |
Shen et al. | Identification of a novel promoter for driving antibiotic-resistant genes to reduce the metabolic burden during protein expression and effectively select multiple integrations in Pichia Pastoris | |
Gurung et al. | Heterologous complementation studies with the YscX and YscY protein families reveals a specificity for Yersinia pseudotuberculosis type III secretion | |
KR101659732B1 (en) | Protein Expression System Induced by Heavy Metals And Biosensor for Detecting Heavy Metals | |
Yun et al. | The CnuK9E H-NS complex antagonizes DNA binding of DicA and leads to temperature-dependent filamentous growth in E. coli | |
Gurvich et al. | Two groups of phenylalanine biosynthetic operon leader peptides genes: a high level of apparently incidental frameshifting in decoding Escherichia coli pheL | |
WO2025081737A1 (en) | Method for forming reversible membraneless organelle in microorganism | |
Mergulhao et al. | Evaluation of inducible promoters on the secretion of a ZZ‐proinsulin fusion protein in Escherichia coli | |
Manna et al. | Altering the selection capabilities of common cloning vectors via restriction enzyme mediated gene disruption | |
Liu et al. | Mini-Tn7 vectors for studying post-transcriptional gene expression in Pseudomonas | |
WO2022138649A1 (en) | A plasmid for transformation, a method for producing a transformant using the same, and a method of transformation | |
Weihmann et al. | The modular pYT vector series employed for chromosomal gene integration and expression to produce carbazoles and glycolipids in P. putida | |
US20070249042A1 (en) | Strains of E. Coli for Plasmid Dna Production | |
AU2016329244A1 (en) | Novel episomal plasmid vectors | |
Zavilgelsky et al. | Sequencing and comparative analysis of the lux operon of Photorhabdus luminescens strain Zm1: ERIC elements as putative recombination hot spots | |
CN117701565B (en) | A strong constitutive promoter of Listeria monocytogenes and its application | |
JP4980483B2 (en) | Yeast and its breeding method | |
WO2016093606A1 (en) | Method for preparing recombinant proteins through reduction of rnpa gene expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: MEDICOSBIOTECH, INC., KOREA, REPUBLIC OF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY;REEL/FRAME:047890/0974 Effective date: 20181220 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |